Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
10 03 2022
10 03 2022
Historique:
received:
15
06
2021
accepted:
17
02
2022
entrez:
11
3
2022
pubmed:
12
3
2022
medline:
5
4
2022
Statut:
epublish
Résumé
The trajectories of acquired immunity to severe acute respiratory syndrome coronavirus 2 infection are not fully understood. We present a detailed longitudinal cohort study of UK healthcare workers prior to vaccination, presenting April-June 2020 with asymptomatic or symptomatic infection. Here we show a highly variable range of responses, some of which (T cell interferon-gamma ELISpot, N-specific antibody) wane over time, while others (spike-specific antibody, B cell memory ELISpot) are stable. We use integrative analysis and a machine-learning approach (SIMON - Sequential Iterative Modeling OverNight) to explore this heterogeneity. We identify a subgroup of participants with higher antibody responses and interferon-gamma ELISpot T cell responses, and a robust trajectory for longer term immunity associates with higher levels of neutralising antibodies against the infecting (Victoria) strain and also against variants B.1.1.7 (alpha) and B.1.351 (beta). These variable trajectories following early priming may define subsequent protection from severe disease from novel variants.
Identifiants
pubmed: 35273178
doi: 10.1038/s41467-022-28898-1
pii: 10.1038/s41467-022-28898-1
pmc: PMC8913789
doi:
Substances chimiques
Antibodies, Viral
0
Antiviral Agents
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251Subventions
Organisme : Medical Research Council
ID : MR/L006588/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204721/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 211153/Z/18/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Investigateurs
Lizzie Stafford
(L)
Hibatullah Abuelgasim
(H)
Ahmed Alhussni
(A)
Carolina V Arancibia-Cárcamo
(CV)
Martyna Borak
(M)
Joseph Cutteridge
(J)
Alexandra Deeks
(A)
Lucy Denly
(L)
Stavros Dimitriadis
(S)
Shayan Fassih
(S)
Thomas Foord
(T)
Thomas Fordwoh
(T)
Jennifer Holmes
(J)
Bryn Horsington
(B)
Sven Kerneis
(S)
David Kim
(D)
Katy Lillie
(K)
Jordan Morrow
(J)
Denise O'Donnell
(D)
Thomas G Ritter
(TG)
Beatrice Simmons
(B)
Adan Taylor
(A)
Sarah R Thomas
(SR)
Yolanda Warren
(Y)
Adam J R Watson
(AJR)
Esme Weeks
(E)
Robert Wilson
(R)
Rebecca Young
(R)
Christopher J A Duncan
(CJA)
Shona C Moore
(SC)
Rebecca Payne
(R)
Alex Richter
(A)
Sarah Rowland-Jones
(S)
Alexander J Mentzer
(AJ)
Mark Philip Cassar
(MP)
Tao Dong
(T)
Anastasia Fries
(A)
Javier Gilbert-Jaramillo
(J)
Ling-Pei Ho
(LP)
Julian C Knight
(JC)
Stefan Neubauer
(S)
Yanchun Peng
(Y)
Nayia Petousi
(N)
Betty Raman
(B)
Nick P Talbot
(NP)
Informations de copyright
© 2022. The Author(s).
Références
Berlin D. A., Gulick R. M., Martinez F. J., Severe Covid-19. N. Engl. J. Med. https://doi.org/10.1056/NEJMcp2009575 (2020).
Eyre, D. W. et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. eLife 9, e60675 (2020).
pubmed: 32820721
pmcid: 7486122
doi: 10.7554/eLife.60675
Fan V. S., et al Risk Factors for testing positive for SARS-CoV-2 in a national US healthcare system. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1624 (2020).
Peng, Y. et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 21, 1336–1345 (2020).
pubmed: 32887977
pmcid: 7611020
doi: 10.1038/s41590-020-0782-6
Ogbe, A. et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nat. Commun. 12, 2055 (2021).
pubmed: 33824342
pmcid: 8024333
doi: 10.1038/s41467-021-21856-3
Wang, Z. et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat. Commun. 12, 1724 (2021).
pubmed: 33741972
pmcid: 7979809
doi: 10.1038/s41467-021-22036-z
Reynolds C. J., et al., Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 5 https://doi.org/10.1126/sciimmunol.abf3698 (2020).
Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/italy-give-just-one-covid-shot-some-patients-eu-struggles-with-inoculations-2021-03-04/ Accessed 13 June 2021.
Lumley S. F., et al., The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin. Infect. Dis., (2021) https://doi.org/10.1093/cid/ciab004 .
Sagar M., et al., Recent endemic coronavirus infection is associated with less-severe COVID-19. J. Clin. Invest. 131 https://doi.org/10.1172/JCI143380 (2021).
Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 Coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501 (2020). e1415.
pubmed: 32473127
pmcid: 7237901
doi: 10.1016/j.cell.2020.05.015
Dan J. M., et al., Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science https://doi.org/10.1126/science.abf4063 (2021).
Ansari, A. et al. Immune memory in mild COVID-19 patients and unexposed donors reveals persistent T cell responses after SARS-CoV-2 Infection. Front Immunol. 12, 636768–636768 (2021).
pubmed: 33777028
pmcid: 7991090
doi: 10.3389/fimmu.2021.636768
Cromer, D. et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immun. 21, 395–404 (2021).
doi: 10.1038/s41577-021-00550-x
Wheatley, A. K. et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 12, 1162–1162 (2021).
pubmed: 33608522
pmcid: 7896046
doi: 10.1038/s41467-021-21444-5
Zuo, J. et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. 22, 620–626 (2021).
pubmed: 33674800
pmcid: 7610739
doi: 10.1038/s41590-021-00902-8
Galanti M., Shaman J., Direct observation of repeated infections with endemic coronaviruses. J. Infect. Dis. https://doi.org/10.1093/infdis/jiaa392 (2020).
Kiyuka, P. K. et al. Human Coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J. Infect. Dis. 217, 1728–1739 (2018).
pubmed: 29741740
doi: 10.1093/infdis/jiy098
Edridge, A. W. D. et al. Seasonal coronavirus protective immunity is short-lasting. Nat. Med 26, 1691–1693 (2020).
pubmed: 32929268
doi: 10.1038/s41591-020-1083-1
Davies N. G., et al., Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 https://doi.org/10.1126/science.abg3055 (2021).
Supasa P., et al., Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell https://doi.org/10.1016/j.cell.2021.02.033 (2021).
Davies, N. G. et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 593, 270–274 (2021).
pubmed: 33723411
doi: 10.1038/s41586-021-03426-1
Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348–2361 (2021). e2346.
pubmed: 33730597
pmcid: 7901269
doi: 10.1016/j.cell.2021.02.037
Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438–443 (2021).
pubmed: 33690265
doi: 10.1038/s41586-021-03402-9
Faria, N. R. et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science 372, 815–821 (2021).
pubmed: 33853970
pmcid: 8139423
doi: 10.1126/science.abh2644
Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939–2954 (2021). e2939.
pubmed: 33852911
pmcid: 8008340
doi: 10.1016/j.cell.2021.03.055
Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).
pubmed: 34237773
doi: 10.1038/s41586-021-03777-9
Skelly, D. T. et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nat. Commun. 12, 5061 (2021).
pubmed: 34404775
pmcid: 8371089
doi: 10.1038/s41467-021-25167-5
Liu, C. et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell 184, 4220–4236 (2021). e4213.
pubmed: 34242578
pmcid: 8218332
doi: 10.1016/j.cell.2021.06.020
Tomic, A. et al. SIMON, an automated machine learning system, reveals immune signatures of influenza vaccine responses. J. Immunol. 203, 749–759 (2019).
pubmed: 31201239
pmcid: 6643048
doi: 10.4049/jimmunol.1900033
Tomic, A. et al. SIMON: open-source knowledge discovery platform. Patterns 2, 100178–100178 (2021).
pubmed: 33511368
pmcid: 7815964
doi: 10.1016/j.patter.2020.100178
Lumley S. F., et al., Antibody status and incidence of SARS-CoV-2 infection in health care workers. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2034545 (2020).
Mathieu E., et al., A global database of COVID-19 vaccinations. Nat. Hum. Behav. https://doi.org/10.1038/s41562-021-01122-8 (2021).
Krammer, F. et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med 384, 1372–1374 (2021).
pubmed: 33691060
doi: 10.1056/NEJMc2101667
Prendecki, M. et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet 397, 1178–1181 (2021).
pubmed: 33640037
pmcid: 7993933
doi: 10.1016/S0140-6736(21)00502-X
Röltgen, K. et al. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci. Immunol. 5, eabe0240 (2020).
pubmed: 33288645
pmcid: 7857392
doi: 10.1126/sciimmunol.abe0240
Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370, 1227 (2020).
pubmed: 33115920
pmcid: 7810037
doi: 10.1126/science.abd7728
Klingler, J. et al. Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory Syndrome Coronavirus 2. J. Infect. Dis. 223, 957–970 (2021).
pubmed: 33367897
doi: 10.1093/infdis/jiaa784
Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).
pubmed: 33288662
doi: 10.1126/scitranslmed.abd2223
Atyeo, C. et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity 53, 524–532 (2020). e524.
pubmed: 32783920
pmcid: 7392190
doi: 10.1016/j.immuni.2020.07.020
Zohar, T. et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell 183, 1508–1519 (2020). e1512.
pubmed: 33207184
pmcid: 7608014
doi: 10.1016/j.cell.2020.10.052
McMahan, K. et al. Correlates of protection against SARS-CoV-2 in Rhesus macaques. Nature 590, 630–634 (2021).
pubmed: 33276369
doi: 10.1038/s41586-020-03041-6
Gorman, M. J. et al. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. Cell Rep. Med. 2, 100405 (2021).
pubmed: 34485950
pmcid: 8405506
doi: 10.1016/j.xcrm.2021.100405
Barrett, J. R. et al. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat. Med. 27, 279–288 (2021).
pubmed: 33335322
doi: 10.1038/s41591-020-01179-4
Kaplonek P., et al., mRNA-1273 vaccine-induced antibodies maintain Fc-effector functions across SARS-CoV-2 Variants of Concern. Immunity https://doi.org/10.1016/j.immuni.2022.01.001 (2022).
Reynolds, C. J. et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 5, eabf3698 (2020).
pubmed: 33361161
pmcid: 8101131
doi: 10.1126/sciimmunol.abf3698
Zuo J., et al., Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat. Immunol. https://doi.org/10.1038/s41590-021-00902-8 (2021).
Ahlers, J. D. & Belyakov, I. M. Memories that last forever: strategies for optimizing vaccine T-cell memory. Blood 115, 1678–1689 (2010).
pubmed: 19903895
pmcid: 2920202
doi: 10.1182/blood-2009-06-227546
Sallusto, F., Lanzavecchia, A., Araki, K. & Ahmed, R. From vaccines to memory and back. Immunity 33, 451–463 (2010).
pubmed: 21029957
pmcid: 3760154
doi: 10.1016/j.immuni.2010.10.008
Wellinghausen, N. et al. SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons. J. Clin. Virol. 130, 104542 (2020).
pubmed: 32707511
pmcid: 7336915
doi: 10.1016/j.jcv.2020.104542
Lynch, K. L. et al. Magnitude and kinetics of anti-severe acute respiratory syndrome Coronavirus 2 antibody responses and their relationship to disease severity. Clin. Infect. Dis. 72, 301–308 (2021).
pubmed: 33501951
doi: 10.1093/cid/ciaa979
Zhao, Y. et al. High levels of virus-specific CD4+ T cells predict severe pandemic influenza A virus infection. Am. J. Respir. Crit. Care Med 186, 1292–1297 (2012).
pubmed: 23087026
doi: 10.1164/rccm.201207-1245OC
Le Bert N., et al., Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J. Exp. Med. 218 https://doi.org/10.1084/jem.20202617 (2021).
Tarke, A. et al. Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals. Cell Rep. Med 2, 100355 (2021).
pubmed: 34230917
pmcid: 8249675
doi: 10.1016/j.xcrm.2021.100355
Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699–5714 (2021). e5611.
pubmed: 34735795
pmcid: 8519781
doi: 10.1016/j.cell.2021.10.011
Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435–446 (1990).
pubmed: 2170159
pmcid: 2271881
doi: 10.1017/S0950268800048019
Ng Kevin, W. et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370, 1339–1343 (2020).
pubmed: 33159009
pmcid: 7857411
doi: 10.1126/science.abe1107
Mallajosyula, V. et al. CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19. Sci. Immunol. 6, eabg5669 (2021).
pubmed: 34210785
doi: 10.1126/sciimmunol.abg5669
pmcid: 8975171
Mateus J., et al., Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science eabd3871 https://doi.org/10.1126/science.abd3871 (2020).
Pouwels K. B., et al., Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med. https://doi.org/10.1038/s41591-021-01548-7 (2021).
Vasileiou, E. et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 397, 1646–1657 (2021).
pubmed: 33901420
pmcid: 8064669
doi: 10.1016/S0140-6736(21)00677-2
Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 373, n1088 (2021).
pubmed: 33985964
doi: 10.1136/bmj.n1088
Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med 384, 2187–2201 (2021).
pubmed: 33882225
doi: 10.1056/NEJMoa2101544
Fischer, R. J. et al. ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. Nat. Commun. 12, 5868 (2021).
pubmed: 34620866
pmcid: 8497486
doi: 10.1038/s41467-021-26178-y
Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478 (2020).
pubmed: 32702298
pmcid: 7445431
doi: 10.1016/S0140-6736(20)31604-4
Frey, A., Di Canzio, J. & Zurakowski, D. A statistically defined endpoint titer determination method for immunoassays. J. Immunol. Methods 221, 35–41 (1998).
pubmed: 9894896
doi: 10.1016/S0022-1759(98)00170-7
Caly, L. et al. Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med J. Aust. 212, 459–462 (2020).
pubmed: 32237278
doi: 10.5694/mja2.50569
Huang, K. A. et al. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 17, e1009352 (2021).
pubmed: 33635919
pmcid: 8130932
doi: 10.1371/journal.ppat.1009352
Binyamin, L. et al. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy. J. Immunol. 180, 6392–6401 (2008).
pubmed: 18424763
doi: 10.4049/jimmunol.180.9.6392
Lesne, E. et al. Acellular pertussis vaccines induce anti-pertactin bactericidal antibodies which drives the emergence of pertactin-negative strains. Front Microbiol 11, 2108–2108 (2020).
pubmed: 32983069
pmcid: 7481377
doi: 10.3389/fmicb.2020.02108
Tomic, A., Tomic, I., Dekker, C. L., Maecker, H. T. & Davis, M. M. The FluPRINT dataset, a multidimensional analysis of the influenza vaccine imprint on the immune system. Sci. Data 6, 214 (2019).
pubmed: 31636302
pmcid: 6803714
doi: 10.1038/s41597-019-0213-4
Fraley, C. & Raftery, A. E. Model-based clustering, discriminant analysis, and density estimation. J. Am. Stat. Assoc. 97, 611–631 (2002).
doi: 10.1198/016214502760047131
Abdi, H. & Williams, L. J. Principal component analysis. Wires Comput. Stat. 2, 433–459 (2010).
doi: 10.1002/wics.101
Wickham H., ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York (2016).
Wood S., Scheipl F. gamm4: Generalized Additive Mixed Models using ‘mgcv’ and ‘lme4’. R package version 0.2-6.) (2020).